Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Martin on Autologous Stem Cell Transplant in Multiple Myeloma

October 12th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Emerging Agents Offer Hope in Late Relapse Myeloma

October 11th 2018

Sandy Wong, MD, discusses emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.

Dr. Valent on MRD Negativity in Multiple Myeloma

October 11th 2018

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Dr. Wong on a Trial With an Anti-CD46 Antibody in Myeloma

October 10th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

Individualized Regimens Instrumental After Early Relapse in Myeloma

October 9th 2018

Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.

High-Dose Chemotherapy and ASCT Reign Supreme in Frontline Myeloma

October 8th 2018

Among new advances in multiple myeloma, high-dose chemotherapy and allogeneic stem cell transplant remain the go-to frontline treatment for patients with newly diagnosed multiple myeloma.

FDA Grants Selinexor Priority Review for Multiple Myeloma

October 7th 2018

The FDA has granted a priority review to a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma.

Expert Discusses Transplant and Emerging Strategies in Myeloma

October 5th 2018

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

Frontline Options Evolving in Newly Diagnosed Myeloma

October 5th 2018

Bita Fakhri, MD, MPH, shares her insight on the treatment of patients with newly diagnosed multiple myeloma.

Dr. Green on Early Relapse in Multiple Myeloma

October 4th 2018

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

NGS Assay for MRD Detection Gains FDA Approval for 2 Blood Cancers

October 3rd 2018

The FDA has approved the next-generation sequencing assay clonoSEQ as a test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia or multiple myeloma.

Dr. Raje on Quadruplet Regimens in Myeloma

October 1st 2018

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

October 1st 2018

The FDA has approved a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

Dr. Zonder on Induction Therapy in Newly Diagnosed Multiple Myeloma

September 26th 2018

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.

Dr. Madduri Discusses Checkpoint Inhibitors in Myeloma

September 20th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the use of checkpoint inhibitors in multiple myeloma.

Expert Addresses Advances and Challenges in Myeloma

September 20th 2018

Andrew Kin, MD, shares his insight on the treatment landscape for multiple myeloma and the challenges that remain.

Dr. Kin on Triplet Regimens for Relapsed Multiple Myeloma

September 18th 2018

Andrew Kin, MD, assistant professor, Karmanos Cancer Institute, discusses triplet regimens for the treatment of patients with relapsed multiple myeloma.

STORM Data Show Encouraging Responses, OS With Selinexor/Dexamethasone in Penta-Refractory Myeloma

September 16th 2018

Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen.

Carfilzomib Combos Deemed Safe in Multiple Myeloma

September 15th 2018

Updated safety data of the ASPIRE and ENDEAVOR trials showed that carfilzomib-based (Kyprolis) regimens demonstrate benefit across patient populations of multiple myeloma.

Dr. Lesokhin on the Current Treatment Landscape of Myeloma

September 14th 2018

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape for patients with multiple myeloma.